WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study-Reference-Cited by-同舟云学术

WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study

Published:2023-07 Issue: Volume:174 Page:239-246
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Embaby Alaa,Kutzera Joachim,Geenen Jill J.,Pluim Dick,Hofland Ingrid,Sanders Joyce,Lopez-Yurda Marta,Beijnen Jos H.,Huitema Alwin D.R.,Witteveen Petronella O.,Steeghs Neeltje,van Haaften Gijs,van Vugt Marcel A.T.M.,de Ridder Jeroen,Opdam Frans L.

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference39 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J. Clin.,2018

2. Ovarian cancer in the world: epidemiology and risk factors;Momenimovahed;Int. J. Women’s Health,2019

3. ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease††;Colombo;Ann. Oncol.,2019

4. Appropriate selection of PARP inhibitors in ovarian Cancer;Smith;Curr. Treat. Options in Oncol.,2022

5. Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents;Leijen;Curr. Clin. Pharmacol.,2010

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2 -Altered Advanced Solid Tumor Malignancies (NCI 10170);Cancer Research Communications;2024-07-01

2. Advanced Design, Synthesis, and Evaluation of Highly Selective Wee1 Inhibitors: Enhancing Pharmacokinetics and Antitumor Efficacy;Journal of Medicinal Chemistry;2024-06-07

3. Drug resistance in ovarian cancer: from mechanism to clinical trial;Molecular Cancer;2024-03-28

4. The power and the promise of synthetic lethality for clinical application in cancer treatment;Biomedicine & Pharmacotherapy;2024-03

5. Translating p53-based therapies for cancer into the clinic;Nature Reviews Cancer;2024-01-29